New research supports sofosbuvir in combination with other antivirals for COVID-19

(Columbia University School of Engineering and Applied Science) Columbia Engineering researchers report that Sofosbuvir-terminated RNA is more resistant to the proofreader of SARS-CoV-2, the virus that causes COVID-19, than Remdesivir-terminated RNA. The results of the new study, published today by the Nature Research journal Scientific Reports, support the use of the FDA-approved hepatitis C drug EPCLUSA--Sofosbuvir/Velpatasvir--in combination with other drugs in COVID-19 clinical trials.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news

Related Links:

Kizzmekia Corbett joins TWiV to review her career and her work on respiratory syncytial virus, influenza virus, and coronaviruses and coronavirus vaccines, including her role in development and testing of a spike-encoding mRNA vaccine, and then we review the Nobel Prize for discovery of hepatitis C virus. Click arrow to playDownload TWiV 670 (76 MB .mp3, […]
Source: virology blog - Category: Virology Authors: Tags: This Week in Virology coronavirus COVID-19 influenza virus mRNA-1273 pandemic prefusion conformation respiratory syncytial virus SARS-CoV-2 spike vaccine viral viruses Source Type: blogs
F, Rizzo LV Abstract BACKGROUND: Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) collection began in two Brazilian hospitals for treatment of severe/critical patients. METHODS AND MATERIALS: Mild/moderate COVID-19 convalescents were selected as CCP donors after reverse transcription polymerase chain reaction (RT-PCR) confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and absence of symptoms for ≥14 days plus (a) age (18-60 years), body weight greater than 55 kg; (b) immunohematological studies; (c) no infectious markers of hepatitis B virus, ...
Source: Transfusion - Category: Hematology Authors: Tags: Transfusion Source Type: research
Many types of viral infections can involve the human cardiovascular, such as Coxsackievirus, parvovirus B19, adenovirus, influenza virus, human herpes virus, Epstein-Barr virus, cytomegalovirus, hepatitis C virus, human immunodeficiency virus (HIV) [1], and even severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is currently circulating worldwide [2]. Zika virus (ZIKV), a type of RNA virus belonging to the family Flaviviridae and genus Flavivirus, was declared a Public Health Emergency of International Concern in February 2016 by the World Health Organization due to the severe damage it causes to the nervous system.
Source: Journal of Molecular and Cellular Cardiology - Category: Cytology Authors: Tags: Letter to the editor Source Type: research
We report 10 candidates with optimal binding features to the active site of the protease for further consideration as potential drugs to treat patients infected with the emerging COVID-19 disease. PMID: 32773989 [PubMed]
Source: Bioinformation - Category: Bioinformatics Authors: Tags: Bioinformation Source Type: research
Vincent visits Ohio State University (March 2020) and speaks with Shan-Lu, David, Amanda, Mark, Matt, Chris, and Qiuhong about their careers and their work on retroviruses, hepatitis C virus, coronaviruses, paramyxoviruses, and environmental viruses. Click arrow to playDownload TWiV 650 (63 MB .mp3, 105 min)Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Show notes at
Source: virology blog - Category: Virology Authors: Tags: This Week in Virology coronavirus COVID-19 hepatitis C virus HTLV pandemic plant viruses retrovirus SARS-CoV-2 viral viroids Source Type: blogs
AbstractBackground and AimCytokine storm has been reported in patients with coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. We examine the incidence of acute on chronic liver failure (ACLF) in COVID-19 patients with pre-existing compensated chronic liver disease (CLD).MethodsFrom 20 Jan 2020 to 7 Feb 2020, we studied 140 consecutive COVID-19 patients admitted to either Fuyang Second People ’s Hospital (FYSPH), Anhui or the Fifth Medical Center of Chinese PLA General Hospital (PLAGH) in Beijing, China. Pre-existing CLD includes those with liver cirrhos...
Source: Hepatology International - Category: Infectious Diseases Source Type: research
CONCLUSION: These promising drugs could inhibit the replication of the virus; hence, we suggest the repurposing of these compounds for thetreatment of COVID-19. No toxicity measurements are required for these drugs since they were previously tested prior to their approval by the FDA. However, the assessment of these potential inhibitors as clinical drugs involves further in vivo tests for these drugs. PMID: 32748740 [PubMed - as supplied by publisher]
Source: Combinatorial Chemistry and High Throughput Screening - Category: Chemistry Authors: Tags: Comb Chem High Throughput Screen Source Type: research
We present an unique circumstance whereas a patient with a 5 year history of inflammatory muscle disease, diagnosed by clinical history and muscle biopsy with elevated creatine kinase levels, suffered a hypoxemic cardiopulmonary arrest due to asymptomatic SARS-CoV-2 after receiving advanced immunosuppressive therapy. Diagnoses: The patient presented with an acute exacerbation of inflammatory muscle disease with dysphagia, muscle weakness, and elevated creatine kinase. Interventions: After no improvement with intravenous immunoglobulin the patient received mycophenolate and plasma exchange therapy. Outcomes: Subseq...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
The impact of SARS-CoV2 in patients with underlying chronic liver disease is still a matter of analysis within the Hepatology community1. We read with great interest several studies suggesting that antivirals against HCV or HBV could be evaluated as COVID-19 therapeutics. A study virtually screening usable therapeutics against SARS-CoV-2 showed that inhibitors of the NS5A protein of the hepatitis C virus (HCV) velpatasvir and ledipasvir were among the 16 candidates which gave promising binding models2.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Letter to the Editor Source Type: research
Abstract COVID-19, is a disease resulting from the SARS-CoV-2 global pandemic. Due to the current global emergency and the length of time required to develop specific antiviral agent(s) and a vaccine for SARS-CoV-2, the world health organization (WHO) adopted the strategy of repurposing existing medications to treat COVID-19. Iron oxide nanoparticles (IONPs) were previously approved by the US food and drug administration (FDA) for anemia treatment and studies have also demonstrated its antiviral activity in vitro. Therefore, we performed a docking study to explore the interaction of IONPs (Fe2O3 and Fe3O4) with th...
Source: European Journal of Pharmaceutical Sciences - Category: Drugs & Pharmacology Authors: Tags: Eur J Pharm Sci Source Type: research
More News: Clinical Trials | COVID-19 | Hepatitis | Hepatitis C | International Medicine & Public Health | SARS | Science | Study